Pharma BD Deal Intelligence
BeiGene and Novartis announced a collaboration and license agreement for the development, manufacturing and commercialization of tislelizumab, BeiGene's…
In January 2021, BeiGene entered into a collaboration and license agreement with Novartis for the development, manufacturing and commercialization of…
BeiGene, Ltd. completed its corporate redomiciliation from the Cayman Islands to Switzerland and renamed to BeOne Medicines Ltd., effective May 27,…
Source summaries from our enrichment pipeline; follow links for originals.
All 19 sources with sentiment breakdown →
Novartis obtained ex-China development and commercialization rights to tislelizumab, BeiGene's anti-PD-1 monoclonal antibody, for $650 million upfront plus up to $1.55 billion in regulatory and sales milestones. BeiGene retained rights in China and other countries. Novartis terminated the partnership in 2023 citing a 'changing PD-1 landscape' and returned all rights to BeiGene. BeiGene subsequently self-launched tislelizumab globally as Tevimbra, winning successive FDA approvals it now holds outright: second-line ESCC (March 2024), first-line HER2-negative gastric/GEJ adenocarcinoma (December 2024), and first-line PD-L1-positive ESCC (2025), alongside earlier EU approvals. In May 2025 the former counterparty renamed itself BeOne Medicines Ltd. and redomiciled to Switzerland. The termination thesis has held: the asset Novartis walked away from has continued a successful independent global launch.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / BeiGene Ltd. (this deal) | 2021 | $2.2B | 40 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2021 deals · Novartis AG deals · Oncology deals